Ignite Creation Date:
2024-05-06 @ 4:20 PM
Last Modification Date:
2024-10-26 @ 2:08 PM
Study NCT ID:
NCT04958239
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2021-07-01
Brief Title:
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer Solid Tumors and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Sponsor:
Organization:
Boehringer Ingelheim
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
160
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: